Introduction: Attention-deficit/hyperactivity disorder (ADHD) is a common and disabling disorder among adults and is treated with stimulant and non stimulant medication. Objective: To report the case of a patient with ADHD showing good clinical response to duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI). Case presentation: A 53 year-old man with a recently diagnosed ADHD was successfully treated with duloxetine 60 mg and showed reduced scores on the Conners' Adult ADHD Rating Scales — Self-Report Scale: Short Version (CAARS-S:S). Conclusion: Duloxetine could be an option for patients who either do not tolerate or show resistance to more common pharmacological choices. Randomized controlled trials are needed to assess the efficacy of duloxetine in treating ADHD symptoms.
Bymaster, F.P., Dreshfield-Ahmad, L.J., Threlkeld, P.G., Shaw, J.L., Thompson, L., Nelson D.L., et al. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25, 871-880.
3.
Spencer, T.T., Biederman, J.J., Wilens, T.T., Harding, M.M., O'Donnell, D.D., & Griffin, S.S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 409-432.
